Multiplying state laws on marketing and distribution disclosures might be pre-empted by new federal legislation
Marketing strategies will adjust with the advent of biosimilars
Applying the managed services model to commercial operations can result in dramatic savings as pharma companies globalize
Multiplying state laws on marketing and distribution disclosures might be pre-empted by new federal legislation
Converging the processes and data from EHRs and from the electronic data-capture (EDC) of the clinical research environment could change the paradigm of drug development and safety
Orphan drug development and marketing have important distinct requirements for R&D, regulatory and marketing
Risk Evaluation & Mitigation Strategy (REMS) programs are evolving, with new complexities for compliance managers
CLM Matrix system exploits Microsoft SharePoint platform
Nearly 30% of acquiring companies do not evaluate FCPA risks prior to an acquisition
Guidance for companies starting out on the commercialization path
What are the risks of future 'pay for delay' settlements between branded and generic manufacturers?
Cold chain packagers balance cost, performance and compliance approaches
When it comes to navigating the complex clinical and commercial landscape for specialty drugs—including hurdles in access to these critical but costly therapies—today’s specialty pharmacies are bringing more skills and services to the table.
Despite the buzz around digital media channels, pharma continues to pour marketing dollars into television
When state and federal governments are involved, prices and reimbursements have both regulatory and financial consequences
A contractual arrangement that could save time and money for brand owners
When a physician prescribes or treats a patient with your specialty drug, the stakes are high for everyone. Patient access is evolving to improve the patient and physician journey with specialty therapies
Recent regulatory actions and court cases highlight the importance of due diligence in reporting the value of service fees when federal reimbursements are concerned. The financial consequences can be substantial
Oncology is the market for today's pipeline products. Here's why the community setting needs to be preserved as a primary site of care to administer those products
Machine learning offers business knowledge based on the data that marketers and sales teams generate
IoT takes you from living in the past to shaping the future
Integrating pharma communications with electronic health-record systems brings value to patients and providers
International efforts to standardize guidelines for observational research could move the entire field forward
Sales Compensation Solutions, a new book from ZS Associates, outlines problems and solutions